{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=43",
    "query": {
      "condition": "Signs and Symptoms, Respiratory",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 4709,
    "total_pages": 471,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Signs+and+Symptoms%2C+Respiratory&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T09:25:27.727Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02805660",
      "title": "Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Mocetinostat - 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Mocetinostat - 70 mg",
          "type": "DRUG"
        },
        {
          "name": "Mocetinostat - 90 mg",
          "type": "DRUG"
        },
        {
          "name": "Mocetinostat - Recommended Phase 2 Dose (70 mg)",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab - 1500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2016-06-01",
      "completion_date": "2019-12-20",
      "has_results": true,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 15,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Pensacola, Florida + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02805660"
    },
    {
      "nct_id": "NCT04377620",
      "title": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2020-05-24",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2022-01-19",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377620"
    },
    {
      "nct_id": "NCT00617318",
      "title": "Pomegranate Products for Prevention of Common Cold",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "Common Cold",
        "Cough",
        "Headache",
        "Fever"
      ],
      "interventions": [
        {
          "name": "Pomegranate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas Heart Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "21 Years to 49 Years"
      },
      "enrollment_count": 461,
      "start_date": "2007-01",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-02-18",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617318"
    },
    {
      "nct_id": "NCT01263808",
      "title": "Cardiac Safety of Indacaterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 µg",
          "type": "DRUG"
        },
        {
          "name": "Indacaterol 300 µg",
          "type": "DRUG"
        },
        {
          "name": "Indacaterol 600 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo/moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 404,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-12-21",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263808"
    },
    {
      "nct_id": "NCT06661889",
      "title": "OM2 Low Saturation Verification",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypoxia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Medtronic - MITG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 28,
      "start_date": "2024-11-18",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06661889"
    },
    {
      "nct_id": "NCT01810510",
      "title": "Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "PAV Ventilation",
          "type": "PROCEDURE"
        },
        {
          "name": "NAVA Ventilation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-04",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01810510"
    },
    {
      "nct_id": "NCT04619680",
      "title": "The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "Interstitial Lung Disease",
        "Respiratory Disease"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2020-11-18",
      "completion_date": "2024-03-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619680"
    },
    {
      "nct_id": "NCT01387230",
      "title": "Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GSK573719",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2011-07-01",
      "completion_date": "2012-02-13",
      "has_results": true,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 4,
      "location_summary": "Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more",
      "locations": [
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        },
        {
          "city": "Union",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01387230"
    },
    {
      "nct_id": "NCT00424528",
      "title": "Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Bronchitis",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "Arformoterol Tartrate Inhalation Solution",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Arformoterol and Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2006-12",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-04",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 28,
      "location_summary": "Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "DeFuniak Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424528"
    },
    {
      "nct_id": "NCT01750281",
      "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV"
      ],
      "interventions": [
        {
          "name": "Selumetinib 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel 75 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel 60 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 212,
      "start_date": "2012-12-18",
      "completion_date": "2022-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-10-24T09:25:27.727Z",
      "location_count": 13,
      "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01750281"
    }
  ]
}